MX2019008921A - Adenovirus recombinante de transgenes múltiples. - Google Patents
Adenovirus recombinante de transgenes múltiples.Info
- Publication number
- MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- multiple transgene
- transgene recombinant
- insertion site
- transgenes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona un adenovirus recombinante que comprende dos (o más) transgenes terapéuticos, por ejemplo, CD80 y CD137L. Dichos transgenes terapéuticos se insertan preferiblemente en un sitio de inserción Elb-19K y/o en un sitio de inserción E3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762452342P | 2017-01-30 | 2017-01-30 | |
US201762520945P | 2017-06-16 | 2017-06-16 | |
PCT/US2018/016032 WO2018140973A1 (en) | 2017-01-30 | 2018-01-30 | Multiple transgene recombinant adenovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008921A true MX2019008921A (es) | 2019-11-08 |
Family
ID=62978741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008921A MX2019008921A (es) | 2017-01-30 | 2018-01-30 | Adenovirus recombinante de transgenes múltiples. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190352616A1 (es) |
EP (1) | EP3574090A4 (es) |
JP (1) | JP2020505049A (es) |
KR (1) | KR20190128634A (es) |
CN (1) | CN110741080A (es) |
AU (1) | AU2018213417A1 (es) |
BR (1) | BR112019015600A2 (es) |
CA (1) | CA3052090A1 (es) |
IL (1) | IL268291A (es) |
MX (1) | MX2019008921A (es) |
SG (1) | SG11201906973TA (es) |
WO (1) | WO2018140973A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
US20200155625A1 (en) * | 2017-05-24 | 2020-05-21 | Epicentrx, Inc. | Anti-angiogenic adenovirus |
WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
EP4349975A1 (en) * | 2021-05-25 | 2024-04-10 | Voncolytic Therapeutics Co., Ltd. | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment |
CN113249342B (zh) * | 2021-05-25 | 2023-12-01 | 江苏万戎生物医药科技有限公司 | 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用 |
WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Il-12 및 4-1bbl을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
US9073980B2 (en) * | 2009-03-02 | 2015-07-07 | The Regents Of The University Of California | Tumor selective E1a and E1b mutants |
KR20180108886A (ko) * | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
ES2759785T3 (es) * | 2012-02-02 | 2020-05-12 | Univ Texas | Adenovirus que expresan antígenos oncógenos heterólogos |
WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
CN103614416B (zh) * | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
PL3198009T3 (pl) * | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-01-30 KR KR1020197025498A patent/KR20190128634A/ko not_active Application Discontinuation
- 2018-01-30 MX MX2019008921A patent/MX2019008921A/es unknown
- 2018-01-30 US US16/482,055 patent/US20190352616A1/en not_active Abandoned
- 2018-01-30 AU AU2018213417A patent/AU2018213417A1/en active Pending
- 2018-01-30 JP JP2019541188A patent/JP2020505049A/ja active Pending
- 2018-01-30 SG SG11201906973TA patent/SG11201906973TA/en unknown
- 2018-01-30 WO PCT/US2018/016032 patent/WO2018140973A1/en unknown
- 2018-01-30 EP EP18743942.7A patent/EP3574090A4/en active Pending
- 2018-01-30 BR BR112019015600-3A patent/BR112019015600A2/pt unknown
- 2018-01-30 CA CA3052090A patent/CA3052090A1/en active Pending
- 2018-01-30 CN CN201880021787.6A patent/CN110741080A/zh active Pending
-
2019
- 2019-07-28 IL IL268291A patent/IL268291A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018213417A1 (en) | 2019-08-15 |
EP3574090A4 (en) | 2021-01-06 |
KR20190128634A (ko) | 2019-11-18 |
WO2018140973A1 (en) | 2018-08-02 |
SG11201906973TA (en) | 2019-08-27 |
BR112019015600A2 (pt) | 2020-03-17 |
US20190352616A1 (en) | 2019-11-21 |
CA3052090A1 (en) | 2018-08-02 |
JP2020505049A (ja) | 2020-02-20 |
EP3574090A1 (en) | 2019-12-04 |
CN110741080A (zh) | 2020-01-31 |
IL268291A (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008921A (es) | Adenovirus recombinante de transgenes múltiples. | |
ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
MX2019004487A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
IL272373A (en) | Methods for factor VIII gene therapy | |
MY185390A (en) | Antisense nucleic acids | |
IL271389A (en) | Non-viral DNA proceeds are intended | |
EP3610025A4 (en) | MULTIPLE TRANSGENIC RECOMBINANT ADENOVIRUS | |
EP4013431A4 (en) | COMBINATION THERAPY WITH GOLD-CONTROLLED TRANSGENES | |
IL287100A (en) | Plasmid system | |
IL279685A (en) | Gene therapy | |
IL284742A (en) | AAV-mediated gene therapy restoring the autoperlin gene | |
GB201805567D0 (en) | Implant alignment system | |
SG11202010676TA (en) | Improved t-cell therapy | |
IL287298A (en) | neurogenesis | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
PT3722434T (pt) | Sistema plasmídico | |
WO2018183692A8 (en) | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
MX2018000984A (es) | Terapias de combinacion. | |
SG11202006740QA (en) | Gaming system | |
GB201817470D0 (en) | Gene therapy | |
GB201802326D0 (en) | Gene therapy | |
IL291520A (en) | Augmented reality public messaging experience | |
SG11202012615VA (en) | Gaming system | |
EP3548036A4 (en) | NATURAL COMBINATION HORMONE REPLACEMENT FORMULAS AND THERAPIES |